Chemomab Therapeutics (CMMB) News Today

→ I’m officially sounding the alarm. (From Altimetry) (Ad)

$0.70

+0.11 (+18.64%)

(As of 04/18/2024 ET)

Source

Source	Headline
	Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis globenewswire.com - April 18 at 7:00 AM
	Chemomab Therapeutics Ltd. (CMMB) finance.yahoo.com - April 8 at 10:37 AM
	Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 globenewswire.com - April 2 at 7:00 AM
	Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis globenewswire.com - March 25 at 7:06 AM
	CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023 investorplace.com - March 7 at 2:01 PM
	Chemomab Therapeutics Ltd: Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update finanznachrichten.de - March 7 at 9:03 AM
	Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update finance.yahoo.com - March 7 at 9:03 AM
	Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference prnewswire.com - March 5 at 7:00 AM
	Biotech Shares Massively Bid Up Before Opening Bell msn.com - February 20 at 12:14 PM
	Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases finance.yahoo.com - February 20 at 7:14 AM
	Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases prnewswire.com - February 20 at 7:00 AM
	Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update finance.yahoo.com - February 14 at 10:32 AM
	Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update prnewswire.com - February 14 at 7:00 AM
	Chemomab Therapeutics to Participate in Upcoming Investor Conferences finance.yahoo.com - February 5 at 10:13 AM
	Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis finance.yahoo.com - January 30 at 8:22 AM
	Chemomab Therapeutics Stock (NASDAQ:CMMB) Dividends: History, Yield and Dates benzinga.com - January 6 at 12:07 PM
	Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 finance.yahoo.com - January 3 at 9:24 AM
	Chemomab Therapeutics Stock (NASDAQ:CMMB) Insider Trades benzinga.com - December 29 at 2:01 AM
	Chemomab Therapeutics Stock (NASDAQ:CMMB), Analyst Ratings, Price Targets, Predictions benzinga.com - December 21 at 2:23 PM
	Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now msn.com - December 6 at 1:43 PM
	Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis finance.yahoo.com - November 16 at 7:31 AM
	US Stocks Gain; Producer Prices Fall In October markets.businessinsider.com - November 15 at 10:35 AM
	Chemomab Reports Fast Track Designation For CM-101 - Quick Facts markets.businessinsider.com - November 15 at 10:35 AM
	Why is Liver Disease Focused Chemomab Stock Trading Higher Today? msn.com - November 15 at 10:35 AM
	Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis finance.yahoo.com - November 15 at 10:35 AM
	Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023 finance.yahoo.com - November 13 at 3:19 PM
	Chemomab Therapeutics, Ltd.: Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update finanznachrichten.de - November 9 at 12:38 PM
	Chemomab Therapeutics GAAP EPS of $0.017 msn.com - November 9 at 12:38 PM
	Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update finance.yahoo.com - November 9 at 12:38 PM
	Chemomab Therapeutics receives Nasdaq notice regarding minimum bid price requirement msn.com - November 6 at 7:11 PM
	Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update finance.yahoo.com - October 30 at 9:29 AM
	Chemomab Therapeutics files for $200M mixed shelf seekingalpha.com - October 16 at 9:10 PM
	Roth MKM Initiates Coverage of Chemomab Therapeutics Ltd - ADR (CMMB) with Buy Recommendation msn.com - October 8 at 5:23 AM
	Roth MKM Initiates Coverage of Chemomab Therapeutics Ltd - ADR (CMMB) with Buy Recommendation msn.com - October 8 at 5:23 AM
	Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference finance.yahoo.com - September 28 at 8:29 AM
	Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference finance.yahoo.com - August 29 at 9:20 AM
	Chemomab Therapeutics, Ltd.: Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update finanznachrichten.de - August 14 at 10:02 AM
	Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update finance.yahoo.com - August 14 at 10:02 AM
	Chemomab Therapeutics Ltd - ADR (CMMB) Price Target Increased by 70.45% to 25.50 msn.com - July 6 at 3:17 PM
	Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis finance.yahoo.com - June 28 at 10:15 AM
	Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023 finance.yahoo.com - June 26 at 8:03 AM
	What's Going On With Chemomab Therapeutics Stock Today msn.com - June 21 at 10:59 AM
	Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 finance.yahoo.com - June 21 at 10:59 AM
	Oppenheimer Downgrades Chemomab Therapeutics Ltd - ADR (CMMB) msn.com - June 7 at 9:41 AM
	Hemomab Therapeutics Reappoints Adi Mor As CEO; Sigal Fattal Reassumes Role Of CFO markets.businessinsider.com - June 5 at 10:27 AM
	Chemomab Therapeutics announces key management changes msn.com - June 5 at 10:27 AM
	Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update finance.yahoo.com - June 5 at 10:27 AM
	Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis finance.yahoo.com - June 2 at 1:22 PM
	Chemomab Therapeutics to Participate in Upcoming Scientific Conferences finance.yahoo.com - May 24 at 8:02 AM
	Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Q1 2023 Earnings Call Transcript finance.yahoo.com - May 16 at 3:05 PM

Get Chemomab Therapeutics News Delivered to You Automatically

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

CMMB Media Mentions By Week

CMMB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CMMB
News Sentiment
▼
0.00

0.53
▲
Average
Medical
News Sentiment

CMMB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CMMB Articles
This Week
▼
1

1
▲
CMMB Articles
Average Week

Get Chemomab Therapeutics News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:CMMB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Chemomab Therapeutics (CMMB) News Today

CMMB Media Mentions By Week

CMMB Media Sentiment

CMMB News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info